Pioneering biogenerics

Learn more about our state-of-the-art biosimilar facility

Explore

Company

Who we are

Alvotech is a privately owned biopharmaceutical company focused on the development and manufacturing of high quality biosimilars for global markets. We are specialists in biotechnology all working towards a common goal ...

Read more

Research and development

WHAT WE DO

We are focused on developing and bringing to market highest quality biosimilars. Our pipeline consists of seven biosimilar monoclonal antibodies aimed at treating cancer, autoimmune, inflammatory and other diseases. 

Read more

Newsroom

Alvotech completes U.S. $300m financing deal

- Fuels growth and biosimilar development in a fast-growing market

Alvotech announced today that it has successfully raised US$300 million through a private bond offering. Net proceeds from the capital raised will be used to fuel continued growth, refinance of existing debt and the further development of Alvotech’s biosimilar assets.

Read More

Meet management

World Class team

Our organizational structure is effective, flexible and has a proven track record that will enable the company to bring new biopharmaceutical products quickly and safely to market. The leadership team is helmed by Rasmus Rojkjaer.

Leadership team

Partnerships

Partnering with Alvotech is gaining access to high quality, ready to market biosimilars


More

We use cookies to ensure our website works properly and to collect statistics about users in order for us to improve the website. Learn more.